Background: Several diazabicyclooctanes (DBOs) are under development as inhibitors of class A and C b-lactamases. Inhibition of OXA (class D) carbapenemases is variable, with those of Acinetobacter spp. remaining notably resistant. We describe a novel DBO, WCK 4234 (Wockhardt), with distinctive activity against OXA carbapenemases.
Introduction
b-Lactam/b-lactamase inhibitor combinations offer one of the best prospects for overcoming the diversity of potent b-lactamases now challenging patient management. Interest centres on diazabicyclooctanes (DBOs) and boronates. 1 The first DBO to be commercialized, avibactam, is licensed in combination with ceftazidime and under Phase II trials with aztreonam. 2 A second analogue, relebactam, is in Phase III trials combined with imipenem/cilastatin. 1 Two further analogues [zidebactam (combined with cefepime) 3 and OP0595/RG6080 4 ] are in earlier-stage clinical development. All these DBOs inhibit class A and C b-lactamases, including extended-spectrum, KPC and AmpC types, whereas none inhibits metallo (class B)-blactamases (MBLs), though these may be out-flanked by using aztreonam, which is stable to MBLs, as the partner b-lactam, 5 or where the DBO itself has antibacterial activity, as with RG6080 (which is active versus Enterobacteriaceae) or zidebactam (which is active against Pseudomonas aeruginosa as well as Enterobacteriaceae). 3, 4 Class D carbapenemases are variably overcome by DBOs. Avibactam inhibits OXA-48-like enzymes 6 and is combined with ceftazidime and aztreonam, 6, 7 which anyway are stable; zidebactam does not inhibit these b-lactamases, but is combined with cefepime, which likewise is stable; 8 relebactam does not inhibit and does not potentiate imipenem against Enterobacteriaceae with OXA-48-like b-lactamases. 9 None of the published analogues protects against the OXA-23, -40, -51 and -58 type carbapenemases that cause most carbapenem resistance in Acinetobacter spp.
We describe here a novel DBO, WCK 4234, which is being developed for combination with meropenem as WCK 5999 (Figure 1) , with distinctive activity against class D b-lactamases, including those of Acinetobacter spp., as well as class A and C types. 
Materials and methods

Isolates
Clinical isolates (n " 348) were referred by UK diagnostic laboratories to PHE for investigation of resistance or were collected during resistance surveys. They were identified using API20E or API20NE strips (bioMérieux, Marcyl' Etoile, France) or by MALDI-TOF MS (Maldi-Biotyper, Brüker, Bremen, Germany), except for Acinetobacter baumannii isolates, which were identified by PCR detection of bla OXA-51-like . 10 Carbapenemase genes were identified by PCR or sequencing. The species split among Enterobacteriaceae with different resistance mechanisms is shown in Table 1 . We also tested previously described AmpC inducibility mutant series of Enterobacteriaceae and P. aeruginosa mutants with different combinations of AmpC inducibility and porin OprD expression.
11,12
Antibiotics and susceptibility testing MICs of imipenem (Wockhardt, Aurangabad, India), meropenem (Sequoia Research Products, Pangbourne, UK) and (as a control) ciprofloxacin combined with WCK 4234 (Wockhardt) at 0, 4 or 8 mg/L were determined by CLSI agar dilution 13 using Mueller-Hinton agar from Oxoid (Thermofisher, Basingstoke, UK). Ceftazidime (Sigma-Aldrich, Poole, UK), with and without avibactam at 4 mg/L (Wockhardt), was tested in parallel as a comparator, as was ertapenem (Wockhardt). Tests were run once with the control strains advised by CLSI and further AMRHAI internal controls with ESBLs and carbapenemases.
Results
Enterobacteriaceae
Susceptibility phenotypes of the clinical isolates to established b-lactams were as expected. Thus, control Enterobacteriaceae without acquired resistance were susceptible to all three carbapenem analogues, as were isolates with only ESBL or AmpC activity, whereas carbapenem resistance was seen in isolates with KPC, MBL, OXA-48 and OXA-181 enzymes and-particularly to ertapenem-in those with combinations of porin loss and AmpC or ESBL activity (Table 2) . Carbapenem MICs were widely scattered for isolates with OXA-48-like (i.e. OXA-48 or OXA-181) carbapenemases, whereas isolates with KPC enzymes or MBLs more consistently showed high-level resistance. Ceftazidime resistance was universal in all groups except for the controls, which were all susceptible, and those with OXA-48-like enzymes, where ceftazidime MICs were bimodally distributed, probably reflecting the co-production or not of ESBLs. Ciprofloxacin resistance was widespread but variable within groups, as reflected by bimodal MIC distributions.
WCK 4234 lacked direct antibacterial activity at up to 128 mg/L and did not potentiate ciprofloxacin (not shown). We therefore consider that its interactions with carbapenems reflected b-lactamase inhibition, not PBP inhibition or permeabilization. Summary MIC data for the clinical isolates, illustrating these interactions with imipenem and meropenem, are shown in Table 2 , with full MIC distributions for isolates with KPC and OXA-48-like enzymes in Table 3 .
WCK 4234, at 4 or 8 mg/L, caused 4-fold or greater reductions in the geometric mean MICs of imipenem and meropenem for: (i) Enterobacteriaceae isolates with combinations of highlevel AmpC or ESBL activity and impermeability; and (ii) Enterobacteriaceae with KPC, OXA-48 and OXA-181 carbapenemases. In all these cases the geometric mean MICs of imipenem and meropenem fell from the intermediate or (generally) resistant range to the susceptible (i.e. 1 mg/L) and, except for a few isolates with KPC carbapenemases, the topmost MICs remained 2!4 mg/L, corresponding to intermediate for the unprotected carbapenems according to CLSI criteria (Table 3) . This 'target' of 4-fold reduction of geometric mean MIC was only narrowly missed for the carbapenem-susceptible AmpC isolates (Table 2) , and 4-to 8-fold potentiation of imipenem and meropenem was widely seen for the AmpC-inducible and AmpC-derepressed Enterobacteriaceae organisms in the isogenic mutant series, though not for the corresponding AmpC-deficient mutants (not shown). These data support the view that AmpC enzymes have a weak protective effect against carbapenems, but only confer resistance if permeability is reduced. 14 Little potentiation of carbapenems, in terms of geometric mean MICs, was seen for control Enterobacteriaceae, lacking potent b-lactamases, or for carbapenem-susceptible ESBL producers, all of which were in any case susceptible to imipenem and meropenem. Nevertheless, for reasons not understood, WCK 4234, at 4 or 8 mg/L, engendered an 2-fold lowering in geometric mean MICs of imipenem, but not meropenem for these groups. No potentiation of carbapenems by WCK 4234 was seen for MBLproducing Enterobacteriaceae, which were consistently resistant to carbapenems and their WCK 4234 combinations.
Ceftazidime/avibactam achieved similarly broad activity to carbapenem/WCK 4234 combinations against the Enterobacteriaceae groups. At its CLSI and EUCAST breakpoint of 8!4 mg/L, and aside from MBL producers, resistance was confined to 1/35 carbapenem-resistant AmpC strains and 1/31 with a KPC carbapenemase. Geometric mean MICs of ceftazidime/avibactam nevertheless were higher than those of the carbapenem/ Mushtaq et al.
WCK 4234 combinations for virtually all test groups of Enterobacteriaceae.
P. aeruginosa
MICs of carbapenems for AmpC-hyperproducing, OprD-deficient P. aeruginosa isolates were reduced 4-fold or more by WCK 4234 at 4 or 8 mg/L (Table 2) Weaker dose-dependent potentiation, with 2-or 3-fold reductions in geometric mean MICs, stronger for imipenem than meropenem, was seen for all other P. aeruginosa groups except MBL producers, which remained highly resistant regardless of WCK 4234. These small, generalized MIC reductions for imipenem, seen also with relebactam, accord with the view that inducible or derepressed AmpC ordinarily gives a small degree of protection against imipenem. 9, 15 Potentiation was also seen for AmpC-inducible and AmpC-derepressed laboratory strains, including those deficient for porin OprD, but not for AmpC-deficient mutants (Table 4) .
With only two representatives it is impossible to be definitive about P. aeruginosa with OXA-48-like carbapenemases; nevertheless, the imipenem and meropenem MICs for these two organisms, both with OXA-181 enzyme, were reduced from 64 to 2-8 mg/L by WCK 4234 at 4 or 8 mg/L (Table 3) .
Avibactam reduced the geometric mean MIC of ceftazidime by 4-fold or more for the AmpC-derepressed P. aeruginosa groups, with a 2-fold effect for cystic fibrosis isolates and little or no effect for other groups. The two OXA-181 isolates were in any case susceptible to ceftazidime at 2-4 mg/L, with these values unaltered by avibactam (Table 2) .
A. baumannii
WCK 4234 achieved strong potentiation of both imipenem and meropenem against isolates with class D carbapenemases, with geometric mean MICs reduced 8-to 40-fold (Table 2 ). For isolates with OXA-23 (the most common carbapenemase in A. baumannii in much of the world 16 ) imipenem and meropenem MICs were reduced to the 2 mg/L CLSI breakpoint, or below, by WCK 4234 at 8 mg/L for 9 of 10 cases (Table 3) , with this target also achieved by 4 mg/L WCK 4234 in the case of meropenem. Similarly good potentiation was seen also for isolates with hyper-produced chromosomal OXA-51 enzymes, whereas WCK 4234-potentiated MICs mostly remained in the intermediate and resistant ranges for isolates with OXA-24/OXA-40 b-lactamases and, for meropenem only, for those with OXA-58 (Table 3) . WCK 4234 had minimal effect on the carbapenem MICs for carbapenem-susceptible control Acinetobacter isolates and for those with AmpC and metallocarbapenemases. Avibactam did not potentiate ceftazidime against any group of A. baumannii isolates ( Table 2) .
Discussion
Carbapenemases present a growing clinical problem, which is compounded by their biochemical and structural diversity and by the geographic associations of particular types. 17 These factors complicate the design of both hydrolysis-evading molecules and inhibitors. KPC enzymes (class A) dominate among 19 NDM types (class B) predominate in the Indian subcontinent, 20 but OXA-181, a sequence variant of OXA-48, is also frequent. Globalization is eroding these geographic patterns and the UK, as an international crossroads, sees similar, albeit small, proportions of Enterobacteriaceae isolates-principally Escherichia coli, Enterobacter spp. and Klebsiella spp. with NDM, KPC and OXA-48-like carbapenemases and a few with VIM and IMP MBLs (PHE, data on file). Also frequent are Enterobacteriaceae with low-level carbapenem resistance via combinations of AmpC or ESBL activity together with impermeability caused by porin loss, 21 though these seem rarely to be implicated in outbreaks. Different carbapenemases, principally the acquired OXA-23, OXA-24/OXA-40 and OXA-58 types, dominate in A. baumannii, though some isolates instead have ISAba1-mediated up-regulation of chromosomal OXA-51 and a few have acquired metallo-enzymes. 22, 23 P. aeruginosa differs from other species in that most carbapenem resistance does not involve acquired carbapenemases. Rather, it arises via mutational loss of porin OprD, a mechanism that requires continued production of AmpC b-lactamase. Efflux augments resistance to meropenem, not imipenem. 24 Minorities of carbapenem-resistant P. aeruginosa isolates have acquired carbapenemases, principally MBLs.
As outlined in the Introduction section, all the DBOs under development protect partner b-lactams against AmpC enzymes and class A b-lactamases, including KPC types. OXA-48-like enzymes are less reliably inhibited, but can be circumvented by combining the DBO with an OXA-48-stable b-lactam (e.g. ceftazidime, cefepime or aztreonam) 5, 7, 8 or where the DBO has direct antibacterial activity, whilst none of the developmental combinations had activity, at accepted breakpoints of the unprotected carbapenems, against A. baumannii with OXA carbapenemases. WCK 4234 thus represents a further advance in DBO development, potentiating carbapenems against Enterobacteriaceae with OXA-48 and OXA-181 enzymes, P. aeruginosa with OXA-181 and, crucially, Acinetobacter spp. with OXA-23, OXA-24/OXA-40, up-regulated OXA-51-like and OXA-58 enzymes.
Besides this unique activity against strains with class D carbapenemases, WCK 4234 behaved like other DBOs 1, 25 in potentiating its partner drugs against Enterobacteriaceae (i) with combinations of AmpC or ESBL activity and impermeability, (ii) P. aeruginosa with AmpC, and (iii) Enterobacteriaceae with KPC carbapenemases. In most cases the MICs of imipenem and meropenem were reduced to below those of ceftazidime/avibactam, though this Diazabicyclooctane WCK 4234 versus class A, C and D b-lactamases JAC advantage may be offset by the high breakpoint (8!4 mg/L) assigned to ceftazidime/avibactam. Generalized weak potentiation of imipenem (less so meropenem) was seen for imipenem against P. aeruginosa, probably reflecting the fact that chromosomal AmpC in this species, whether inducible or derepressed, gives some protection against this carbapenem. 15 Similar generalized potentiation of imipenem against P. aeruginosa is seen with relebactam 9 and AmpC-inhibiting penems and monobactams. 26, 27 In many cases (exceptions were a few Enterobacteriaceae with combinations of AmpC and impermeability or KPC enzymes, several P. aeruginosa groups and A. baumannii with OXA-24/OXA-40 or, for meropenem only, with OXA-58 enzymes) even the highest MICs of carbapenem/WCK 4234 combinations were within the current CLSI and EUCAST breakpoints for the unprotected molecules, suggesting significant potential utility. Except in the case of A. baumannii with OXA-58 enzymes, which are uncommon, there was little difference in performance between the imipenem and meropenem combinations, meaning that partnering decisions will best be predicated on chemical stability, ease of formulation, dosing flexibility, scope for prolonged infusion and resistance to inactivation by renal dehydropeptidase, rather than microbiological spectrum. These factors support the use of meropenem as a partner.
